How Moderna Came up With a Vaccine Against Vaccine Dissent: Lee Fang
Finances at the vaccine manufacturer Moderna began to fall almost as quickly as they had risen, as most Americans resisted getting yet another COVID booster shot. The pharmaceutical company, whose pioneering mRNA vaccine had turned it from small startup to biotech giant worth more than $100 billion in just a few years, reported a third-quarter loss last year of $3.6 billion, as most Americans refused to get another COVID booster shot.
In a September call aimed at shoring up investors, Moderna’s then–chief commercial officer, Arpa Garay, attributed some of the hesitancy pummeling Moderna’s numbers to uninformed vaccine skeptics. “Despite some misinformation,” Garay said, COVID-19 still drove significant hospitalizations. “It really is a vaccine that’s relevant across all age groups,” she insisted.
To get past the “misinformation” and convince the public to take continual booster shots, Garay briefly noted that Moderna was “delving down” on ways to partner “across the ecosystem to make sure consumers are educated on the need for the vaccine.”
What Garay hinted at during the call, but didn’t disclose, was that Moderna already had a sprawling media operation in place aimed at identifying and responding to critics of vaccine policy and the drug industry. A series of internal company reports and communications reviewed by RealClearInvestigations show that Moderna has worked with former law enforcement and public health officials and a drug industry-funded non-governmental organization called The Public Good Projects (PGP) to confront the “root cause of vaccine hesitancy” by rapidly identifying and “shutting down misinformation.”
Part of this effort includes providing talking points to some 45,000 healthcare professionals “on how to respond when vaccine misinformation goes mainstream.” PGP and Moderna have created a new partnership, called the “Infodemic Training Program,” to prepare health care workers to respond to alleged vaccine-related misinformation.
The company has also used artificial intelligence to monitor millions of global online conversations to shape the contours of vaccine-related discussion. The internal files — shorthanded here as the Moderna Reports — show high-profile vaccine critics were closely monitored, particularly skeptics in independent media, including Michael Shellenberger, Russell Brand, and Alex Berenson. PGP, which was funded by a $1,275,000 donation from the Biotechnology and Innovation Organization, a lobby group representing Pfizer and Moderna, has identified alleged vaccine misinformation and helped facilitate the removal of content from Twitter, among other social media platforms, throughout 2021 and 2022.
“People opposed to vaccines are capitalizing on the NYT [New York Times] article about the CDC withholding vaccine information. The articles do not contain misinformation themselves but are using the news to further prove the CDC is untrustworthy,” wrote Savannah Knell, PGP’s senior director of partnerships, in an email to a Twitter lobbyist in September 2022. In another email the following month, Kaitlyn Krizanic, PGP’s senior program manager, told Twitter to be on the lookout for “reports that Sweden is no longer recommending the vaccine for children.” In some cases, conservative accounts expressing outrage at restrictive pandemic policies, such as vaccination passports, were deemed by PGP as “misinformation” that warranted removal.
The Moderna Reports consistently show the company raising red flags about those reporting documented side effects of the vaccine the biotech company was selling. Such concerns, which may be typical of corporate public relations efforts that want their product shown in the best light, take on a darker cast when it involves medicine injected into people’s bodies.
Like the Twitter Files, the Moderna Reports highlight the push by powerful entities – especially government, Big Tech, and Big Pharma – to identify and brand dissenting opinions about establishment narratives as risky forms of speech. The growing network these efforts rely on shows the growth of what has been called the censorship industrial complex. Moderna’s faltering financials also suggest, at least for now, the limits of that project.
In an internal email sent last July, Moderna notified its team of its latest efforts to shape the vaccine debate. “We have partnered with PGP (The Public Good Projects) and Moderna’s Global Intelligence, Corporate Security, Medical Affairs, Corporate Communications, Clinical Safety and Pharmacovigilance teams to provide media monitoring for misinformation at scale,” Marcy Rudowitz, the company’s customer program lead, wrote. “If and when a response is needed, our team will notify the appropriate stakeholders with recommendations,” she added.
The extent to which the company may intervene to shape content decisions is not clear. PGP continues to boast close relations with establishment institutions, including major medical associations.
The rise of censorship is inextricably connected to the pandemic, which emerged in the U.S. in early 2020. As federal, state, and local governments imposed unprecedented regulations on Americans in the name of public health, efforts arose to discredit counter-narratives that could be spread easily on social media. Early in the pandemic, criticism of policies such as lockdowns and vaccine mandates came almost entirely from independent media, which faced shadowbans and outright censorship on various platforms.
When they introduced their vaccines in 2021, manufacturers such as Moderna, Pfizer, and Johnson & Johnson also had a powerful financial interest in bolstering such censorship.
Moderna, perhaps more than other drug firms, is overwhelmingly reliant on the continued success of its vaccine. The company announced a price hike of up to $130 a dose this month, far higher than the $15-26 for American federal contracts, according to the Wall Street Journal. “We’re expecting a 90% reduction in demand,” Modena CEO Stéphane Bancel said, when he was asked to defend the decision. “As you can see, we’re losing economies of scale.”
